 |
|
|
|
Diferentes formulaciones conteniendo una fracción hidrosoluble, purificada y estandarizada de los frondes, registrada como EXPLY-37, han sido desarrolladas y usadas como suplementos nutricionales. Estas formulaciones han mostrado actividad en la reversión en el Síndrome de Sobrentrenamiento y Fatiga Crónica. El Phlebodium decumanum ha mostrado actividad en la reversión del síndrome de Sobrentrenamiento en atletas y demás personas practicantes de deportes. Este producto puede también ser usado en personas que sufren del Síndrome de Fatiga Crónica (CFS). Sports performance, oxidative metabolism and immune function: Effects of Phlebodium decumanum (EXPLY). Abstract:
TCycling is a sport characterized by special energy requirements due to the high competition demands: daily, high energy expenditure stages for 1 to 3 weeks without sufficient recovery periods. Overcharge, muscle fatigue and overtraining syndrome are common among cyclists and are associated to a pattern of immune disfunction characterized by overexpression of pro-inflammatory cytokines. EXPLY-37 is a purified and standardized water-soluble fraction obtained from the leaves of Phlebodium decumanum, a fern organically cultivated and processed in the Yojoa lake pure monocultures (Honduras). Different formulations containing EXPLY-37 have shown a modulating effect on the release of TNF induced in different cell lines by various stimulii. The aim of this study was to investigate the effect of Phlebodium decumanum on cycling performance and to explore the eventual correlation with the prevention of oxidative stress and immune disfunction. 18 cyclists were submitted to intensive aerobic training. They randomly received either Phlebodium decumanum, as a nutritional supplement, or placebo for 4 weeks. Parameters related to performance, oxidative damage and immune disfunction were compared at T1 (4 week training) and T0 (basal). Overall performance was improved in the group receiving Phlebodium decumanum, as shown by the increase in maximal aerobic work (watts) (367.5±16.87 vs 340±17.48, p=0.0005) maximal respiratory quotient (1.43±0.20 vs 1.25±0.05, p=0.05) and maximal lactate concentration (mmol/L) (11.64±1.5 vs 10.15±1.68, p=0.0005). These data are analyzed in connection with those related to the enhancement of oxidative metabolism (plasma CoQ10 and a-tocopherol levels) and to the prevention of oxidative stress (mitochondrial lymphocyte DNA damage). They appear to be in close relationship with the activity of Phlebodium decumanum in the regulation of certain cytokines and their receptors involved in the inflammatory response associated to the overtraining syndrome, and support the use of EXPLY-37 formulations as nutritional supplements in the prevention of overcharge, muscle fatigue and overtraining. In vitro anti-inflammatory activity of Phlebodium decumanum. Modulation of tumor necrosis factor and soluble TNF receptors . Abstract: The immunomodulatory activity of a standardized water soluble fraction of the fern Phlebodium decumanum (EXPLY-37®) previously shown to have "in vivo" anti-inflammatory activity was analyzed "in vitro". This extract inhibited tumor necrosis factor (TNF) production by macrophages activated with lipopolysaccharide (LPS) or LPS plus interferon (IFN)- . In contrast, nitric oxide (NO) and interleukin (IL)-1 production were not affected in the same cultures, whereas IL-6 production was partially inhibited. More interestingly, EXPLY-37® increased the release of soluble TNF-receptor 2 (sTNFR2) and of IL-1R antagonist (IL-1Ra) but not of sTNFR1, by activated macrophages. EXPLY-37® had no effect on T lymphocyte activation, measured as proliferation as well as expression of early and late cell surface antigens CD69, CD25 (IL-2R- ) and CD71 (transferrin receptor) at the cell membrane. At the molecular level, EXPLY-37® did not inhibit the activation of the nuclear factor kappa B (NF- B) transcription factor by TNF. In summary, EXPLY-37® has two anti-inflammatory activities "in vitro": it decreases TNF production and increases IL-1Ra and sTNFR2, which may be able to neutralize IL-1 and TNF activity, respectively. International Immunopharmacology. |
Helsint S.A.L helsint@helsint.com
Hay evidencia de que las formulaciones a base de la variedad de Phlebodium decumanum, orgánicamente cultivado y procesado en la factoría del lago Yojoa, pueden ser de gran valor en la mejoría de la calidad de vida, y en la evolución de la enfermedad, en situaciones donde una disfunción inmune esté relacionada con la sobreproducción de citokinas.